US Stock Market Move | AI will be used to develop weight loss drugs, and Novo Nordisk A/S Sponsored ADR Class B (NVO.US) has increased by nearly 2% against the trend.
On Friday, Novo Nordisk (NVO.US) defied the trend and rose nearly 2%, closing at $86.77.
On Friday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose nearly 2% against the market trend, closing at $86.77 USD. In terms of news, the company and the U.S. technology company Valo Health recently announced their agreement to expand the scope of their collaboration to develop up to 11 drugs by 2023, utilizing human data and artificial intelligence (AI) to develop up to 20 new therapies for obesity, type 2 diabetes, and cardiovascular diseases.
RECOMMEND
For the Third Consecutive Month, China Reduces U.S. Treasury Holdings by $900 Million in May, While Japan and the United Kingdom Increase Holdings
18/07/2025
Tariff-Driven Inflation Arrives with Delay as U.S. Consumers Begin to Feel the Initial Pinch
18/07/2025
Multiple Countries in High-Stakes Talks with the U.S.; EU Considers Invoking “Anti-Coercion Tool” as U.S. Plans Unified Tariffs on 150 Nations
18/07/2025
